Health Care

Biotechnology

15 companies under coverage.

Coverage

Biotechnology

Neurocrine Biosciences Inc (NBIX)

HOLD. 12-month probability-weighted target $172 (+11% vs spot). P/E Multiple explains 71% of Monte Carlo outcome variance.

NBIXEquity ResearchMonte Carlo

9 September 2026Rating: HOLD · +0.6%

Equity Research

United Therapeutics Corporation (UTHR)

HOLD. 12-month probability-weighted target $516 (+4% vs spot). P/E Multiple explains 86% of Monte Carlo outcome variance.

UTHREquity ResearchMonte Carlo

9 September 2026Rating: HOLD · -0.2%

Equity Research

Biomarin Pharmaceutical Inc (BMRN)

SELL. 12-month probability-weighted target $59 (-8% vs spot). P/E Multiple explains 78% of Monte Carlo outcome variance.

BMRNEquity ResearchMonte Carlo

9 September 2026Rating: SELL · -5.7%

Equity Research

Exelixis Inc (EXEL)

HOLD. 12-month probability-weighted target $57 (-2% vs spot). P/E Multiple explains 92% of Monte Carlo outcome variance.

EXELEquity ResearchMonte Carlo

9 September 2026Rating: HOLD · -7.4%

Equity Research

Incyte Corporation (INCY)

SELL. 12-month probability-weighted target $107 (-14% vs spot). P/E Multiple explains 78% of Monte Carlo outcome variance.

INCYEquity ResearchMonte Carlo

9 September 2026Rating: SELL · -8.1%

Equity Research

Biogen Inc (BIIB)

SELL. 12-month probability-weighted target $194 (-8% vs spot). P/E Multiple explains 68% of Monte Carlo outcome variance.

BIIBEquity ResearchMonte Carlo

9 September 2026Rating: SELL · -15.1%

Equity Research

AbbVie Inc (ABBV)

HOLD. 12-month probability-weighted target $236 (-5% vs spot). P/E Multiple explains 84% of Monte Carlo outcome variance.

ABBVEquity ResearchMonte Carlo

9 September 2026Rating: HOLD · -15.7%

Equity Research

Vertex Pharmaceuticals Inc (VRTX)

SELL. 12-month probability-weighted target $466 (-12% vs spot). P/E Multiple explains 84% of Monte Carlo outcome variance.

VRTXEquity ResearchMonte Carlo

9 September 2026Rating: SELL · -17.8%

Equity Research

Gilead Sciences Inc (GILD)

SELL. 12-month probability-weighted target $122 (-17% vs spot). P/E Multiple explains 81% of Monte Carlo outcome variance.

GILDEquity ResearchMonte Carlo

9 September 2026Rating: SELL · -22.4%

Equity Research

Amgen Inc (AMGN)

SELL. 12-month probability-weighted target $355 (-10% vs spot). P/E Multiple explains 80% of Monte Carlo outcome variance.

AMGNEquity ResearchMonte Carlo

9 September 2026Rating: SELL · -22.6%

Equity Research

Regeneron Pharmaceuticals Inc (REGN)

SELL. 12-month probability-weighted target $617 (-24% vs spot). P/E Multiple explains 80% of Monte Carlo outcome variance.

REGNEquity ResearchMonte Carlo

9 September 2026Rating: SELL · -25.3%

Equity Research

Repligen Corporation (RGEN)

SELL. 12-month probability-weighted target $126 (-25% vs spot). P/E Multiple explains 76% of Monte Carlo outcome variance.

RGENEquity ResearchMonte Carlo

9 September 2026Rating: SELL · -27.8%

Equity Research

Halozyme Therapeutics Inc (HALO)

SELL. 12-month probability-weighted target $79 (-27% vs spot). P/E Multiple explains 88% of Monte Carlo outcome variance.

HALOEquity ResearchMonte Carlo

9 September 2026Rating: SELL · -33.1%

Equity Research

Cytokinetics Inc (CYTK)

SELL. 12-month probability-weighted target $23 (-70% vs spot). P/E Multiple explains 89% of Monte Carlo outcome variance.

CYTKEquity ResearchMonte Carlo

9 September 2026Rating: SELL · -73.1%

Equity Research

Arrowhead Pharmaceuticals Inc (ARWR)

SELL. 12-month probability-weighted target $22 (-74% vs spot). P/E Multiple explains 90% of Monte Carlo outcome variance.

ARWREquity ResearchMonte Carlo

9 September 2026Rating: SELL · -75.5%